Name | Value |
---|---|
Revenues | 253.0K |
Cost of Revenue | 1,552.0K |
Gross Profit | -1,299.0K |
Operating Expense | 4,222.0K |
Operating I/L | -3,969.0K |
Other Income/Expense | -456.0K |
Interest Income | 843.0K |
Pretax | -4,425.0K |
Income Tax Expense | 3.0K |
Net Income/Loss | -4,371.0K |
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company specializing in the development and commercialization of therapies for acute pain treatment. Its primary product candidate, DSUVIA and DZUVEO, is a 30 mcg sufentanil sublingual tablet designed for moderate-to-severe acute pain. The company also develops ZALVISO, a patient-controlled analgesia system for hospital patients, ARX-02 for cancer breakthrough pain, and 4ARX-03 for mild sedation and pain relief during procedures. Additionally, it is exploring Niyad, a regional anticoagulant, and LTX-608, a nafamostat formulation for antiviral treatment. AcelRx Pharmaceuticals, Inc. generates revenue through the development and commercialization of these pain management therapies.